These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1634046)

  • 1. Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation: implications for gene therapy.
    Vemuru RP; Davidson A; Aragona E; Chowdhury JR; Burk RD; Gupta S
    FASEB J; 1992 Jul; 6(10):2836-42. PubMed ID: 1634046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel system for transplantation of isolated hepatocytes utilizing HBsAg-producing transgenic donor cells.
    Gupta S; Chowdhury NR; Jagtiani R; Gustin K; Aragona E; Shafritz DA; Chowdhury JR; Burk RD
    Transplantation; 1990 Sep; 50(3):472-5. PubMed ID: 2402796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocytes exhibit superior transgene expression after transplantation into liver and spleen compared with peritoneal cavity or dorsal fat pad: implications for hepatic gene therapy.
    Gupta S; Vemuru RP; Lee CD; Yerneni PR; Aragona E; Burk RD
    Hum Gene Ther; 1994 Aug; 5(8):959-67. PubMed ID: 7948145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte transplantation: an alternative system for evaluating cell survival and immunoisolation.
    Gupta S; Kim SK; Vemuru RP; Aragona E; Yerneni PR; Burk RD; Rha CK
    Int J Artif Organs; 1993 Mar; 16(3):155-63. PubMed ID: 8314640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen.
    Schirmbeck R; Wild J; Stober D; Blum HE; Chisari FV; Geissler M; Reimann J
    J Immunol; 2000 Apr; 164(8):4235-43. PubMed ID: 10754320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells.
    Kurose K; Akbar SM; Yamamoto K; Onji M
    Immunology; 1997 Dec; 92(4):494-500. PubMed ID: 9497491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.
    Shimizu Y; Guidotti LG; Fowler P; Chisari FV
    J Immunol; 1998 Nov; 161(9):4520-9. PubMed ID: 9794377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
    Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
    Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcatheter hepatocyte transplantation: preclinical studies of anatomic consequences in the portal vascular bed.
    Kerr A; Rajvanshi P; Gupta S
    Acad Radiol; 1994 Nov; 1(3):229-36. PubMed ID: 9419491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction and maintenance of anti-HBs in immunosuppressed murine hepatitis B virus carriers by a novel vaccination approach: implications for use in hepatitis B virus-infected subjects with liver transplantation.
    Furukawa S; Akbar SM; Hasebe A; Horiike N; Onji M
    J Gastroenterol; 2004 Sep; 39(9):851-8. PubMed ID: 15565404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo immunogenicity of purified allogeneic hepatocytes in a murine hepatocyte transplant model.
    Bumgardner GL; Li J; Heininger M; Ferguson RM; Orosz CG
    Transplantation; 1998 Jan; 65(1):47-52. PubMed ID: 9448143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice.
    Wang Y; Chen K; Wu Z; Liu Y; Liu S; Zou Z; Chen SH; Qu C
    Int J Infect Dis; 2014 Dec; 29():31-6. PubMed ID: 25449231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation.
    Ponder KP; Gupta S; Leland F; Darlington G; Finegold M; DeMayo J; Ledley FD; Chowdhury JR; Woo SL
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1217-21. PubMed ID: 1899924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
    Wirth S; Guidotti LG; Ando K; Schlicht HJ; Chisari FV
    J Immunol; 1995 Mar; 154(5):2504-15. PubMed ID: 7868916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.
    Malanchère-Brès E; Payette PJ; Mancini M; Tiollais P; Davis HL; Michel ML
    J Virol; 2001 Jul; 75(14):6482-91. PubMed ID: 11413315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection.
    Loirat D; Mancini-Bourgine M; Abastado JP; Michel ML
    Int Immunol; 2003 Oct; 15(10):1125-36. PubMed ID: 13679383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants.
    Schirmbeck R; Dikopoulos N; Kwissa M; Leithäuser F; Lamberth K; Buus S; Melber K; Reimann J
    Eur J Immunol; 2003 Dec; 33(12):3342-52. PubMed ID: 14635042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.